EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study

Kaamini Planisamy, Elena Ctori, Benhur Amanuel iD, Emma R Allanson iD, Chloe Ayres, Martin Buck, Giselle Howard, Yee Leung iD, Tarek Meniawy iD, G Raj K A Mohan, Cassandra B Nichols iD, Navin David Pallayoor und 1 weitere

Cancer Reports · 2025

DOI: 10.1002/cnr2.70335 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Reports, 2025. Verfasst von Kaamini Planisamy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Western Australia Gynaecological Cancer Service, King Edward Memorial Hospital, Subiaco, Western Australia, Australia. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Homologous Recombination, Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Poly‐ADP ribose polymerase inhibitors have been shown to improve progression‐free survival in patients with advanced high‐grade epithelial non‐mucinous ovarian cancers characterized by a deficiency in homologous recombination (HRD). Guidelines recommend all patients with advanced high‐grade epithelial ovarian cancer undergo genomic tumor testing for HRD. Our aim was to evaluate the first year of HRD testing at the statewide Western Australia Gynecologic Cancer Service to assess factors associated with obtaining a diagnostic HRD testing result.

Methods

Retrospective chart review.

Results

HRD testing was indicated in 84 patients, and ordered in 79, of which three had non‐diagnostic/inconclusive results, all due to insufficient tumor quantity. One patient had the sample collected using a 20‐gauge core biopsy needle under image guidance, one patient following interval debulking surgery, and one following primary debulking surgery. Of 76 patients with an HRD result, HRD was positive in 29 (38.2%). A somatic BRCA mutation was detected in six of these 29 patients (20.6%) and HRD positive, BRCAwt was detected in 23 of 29 patients (79.4%). All core biopsies with 16‐ and 18‐gauge needles had a diagnostic HRD result. Ten of 11 patients who were treated by neoadjuvant chemotherapy and whose biopsies were obtained at interval cytoreductive surgery had sufficient tumor tissue for testing and had a diagnostic HRD result. All ascitic/pleural fluid samples sent for HRD testing yielded diagnostic results.

Conclusions

Compliance with HRD testing was high, and only three of 79 (3.8%) patients had non‐diagnostic results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Ovarian EpithelialOvarian NeoplasmsHomologous RecombinationGenetic TestingHumansFemaleMiddle AgedRetrospective StudiesWestern AustraliaAgedAdultNeoplasm GradingMutationBRCA2 ProteinAged, 80 and overCytoreduction Surgical ProceduresBRCA1 ProteinPoly(ADP-ribose) Polymerase Inhibitors

Stichwörter der Autor:innen

HRD testinghomologous recombination deficiency (HRD)ovarian cancerpoly‐ADP ribose polymerase inhibitors

Substanzen

BRCA2 protein, humanBRCA2 ProteinBRCA1 protein, humanBRCA1 ProteinPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Western Australia Gynaecological Cancer Service, King Edward Memorial Hospital, Subiaco, Western Australia, Australia.
  • PathWest Molecular Anatomical Pathology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Western Australia, Australia.
  • Division of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.
  • Queen Elizabeth II Cancer Centre, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Western Australia, Australia.
  • Genetic Health Western Australia, King Edward Memorial Hospital, Subiaco, Western Australia, Australia.

ORCID-Profile: Benhur Amanuel, Emma R Allanson, Yee Leung, Tarek Meniawy, Cassandra B Nichols, Paul A Cohen

Zitieren

APA

Planisamy, K., Ctori, E., Amanuel, B., Allanson, E. R., Ayres, C., Buck, M., Howard, G., Leung, Y., Meniawy, T., Mohan, G. R. K. A., Nichols, C. B., Pallayoor, N. D., & Cohen, P. A. (2025). Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study. Cancer Reports. https://doi.org/10.1002/cnr2.70335

Vancouver

Planisamy K, Ctori E, Amanuel B, Allanson ER, Ayres C, Buck M, et al. Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study. Cancer Reports. 2025. doi:10.1002/cnr2.70335

BibTeX
@article{Planisamy2025,
  author = {Planisamy, Kaamini and Ctori, Elena and Amanuel, Benhur and Allanson, Emma R and Ayres, Chloe and Buck, Martin and Howard, Giselle and Leung, Yee and Meniawy, Tarek and Mohan, G Raj K A and Nichols, Cassandra B and Pallayoor, Navin David and Cohen, Paul A},
  title = {Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70335}
}
Kostenlos starten →